Skip to main content
OpenTrials
Completed

NCT Number: NCT03595891

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

A study based on a chart review of participants that presented with a sudden blood clot in the lung

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Embolism (PE) Cardiovascular Diseases Embolism Embolism and Thrombosis Lung Diseases Pulmonary Embolism Pulmonary Thromboembolism Respiratory Tract Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Cardiff, CF23 8RS, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults participants at date of admission
  • Primary presentation consistent with PE followed by objectively-confirmed acute PE
  • Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge

Exclusion criteria

  • PE diagnosed during a hospital admission for a reason other than PE during the study period
  • Patients receiving anticoagulation at the time of presentation
  • Patients presenting outside the defined study period

Other protocol defined inclusion/exclusion criteria could apply

Treatment and study plan

Non-Interventional

Other

Non-Interventional

Primary outcomes

  1. Compare the average length of stay in secondary care

    Time frame: 60 days

Secondary outcomes

  1. Total length of stay, including repeat admissions

    Time frame: During the first 30 days after presentation of PE

  2. Distribution of clinical characteristics of patients admitted with a PE

    Time frame: Baseline

    Clinical characteristics will be summarized using descriptive statistics

  3. Distribution of demographic data of patients admitted with a PE

    Time frame: Baseline

    Demographic data will be summarized using descriptive statistics

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Jul 23, 2018
Registry last updated
May 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.